Taiwan Biosimilars Industry Starting To Take Shape

TAIPEI, Taiwan – With a number of novel biologics looking good in late-stage multisite FDA- or EMA-authorized clinical trials, Taiwan’s biopharmaceutical sector is starting to fulfill its early promise, rewarding the faith of its backers – both government and private sector – after decades of slow progress. Local production capacity is now ramping up; at least seven companies have their own manufacturing facilities and more are on the way.

To continue reading subscribe now to BioWorld Asia (formerly International)